Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 In furtherance to the intimation, captioned "US FDA Inspection at Alkem's manufacturing facility located at St. Louis, USA" dated 6th February, 2019 and 22nd March, 2019, this is to inform you that the Company has received a letter from the US FDA classifying the inspection conducted at its St. Louis facility as Official Action Indicated (OAI). St. Louis facility contributes about 2% of the Company's total US revenues or about 0.5% of the Company's consolidated revenues. The Company believes that this classification will not have any significant impact on existing supplies or the existing revenues from the operations of this facility. The Company shall continue to work closely with US FDA to close out all the observations associated with this inspection. Kindly take the same on record.
15-05-2019
Bigul

Alkem Laboratories Ltd - 539523 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prasid Uno Family Trust
02-05-2019
Bigul

Alkem Laboratories Ltd - 539523 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayAlkem Laboratories Ltd 2CININE540L01014 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0 4Highest Credit Rating during the previous FY AA+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: MANISH NARANG Designation: PRESIDENT LEGAL COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: manishnarang@alkem.com Name of the Chief Financial Officer: RAJESH DUBEY Designation: PRESIDENT FINANCE AND CFO EmailId: rajeshdubey@alkem.com Date: 25/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
25-04-2019
Bigul

Alkem Laboratories Ltd - 539523 - Certificate Under Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31St March, 2019.

 In terms of Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Certificate received from Practising Company Secretary for the half year ended 31st March, 2019. Kindly take the same on record.
19-04-2019
Bigul

Alkem Laboratories Ltd - 539523 - Shareholding for the Period Ended March 31, 2019

 Alkem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here
12-04-2019
Bigul

Alkem Laboratories Ltd - 539523 - Statement Of Investor Complaints For The Quarter Ended March 2019

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Mr Manish NarangDesignation :- Company Secretary and Compliance Officer
09-04-2019
Bigul

Alkem Laboratories Ltd - 539523 - Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 As per the requirement of Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both, physical and electronic share transfer facility for Alkem Laboratories Limited (hereinafter referred to as 'the Company') are maintained during the period from 1st October, 2018 to 31st March, 2019 (both days inclusive) by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is registered as Registrar & Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number: INR000004058.
02-04-2019
Bigul

Alkem Laboratories Ltd - 539523 - Closure of Trading Window

 This is to inform you that in terms of Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 30th March, 2019 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and year ended 31st March, 2019 are communicated to the Stock Exchanges.
29-03-2019
Bigul

USFDA withholds product approval from Alkem's US facility

 Alkem Laboratories on Friday informed the exchanges that it has received a letter from the US Food and Drug Administration directing it to withhold th
22-03-2019
Bigul

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 In furtherance to the intimation captioned "US FDA Inspection at Alkem's manufacturing facility located at St. Louis, USA" dated 6th February, 2019, this is to inform you that the Company had submitted a detailed response to the eight (8) Form 483 observations that it had received during a pre-approval inspection for a product at the Company's manufacturing facility located at St. Louis, USA. The Company has now received a letter from the US FDA informing that the manufacturing of the said product be withheld until the completion of the final evaluation by the USFDA and the final decision of the US FDA shall be communicated to the Company accordingly. It is to be noted that the said product is not being manufactured at this time as it is awaiting approval from US FDA.
22-03-2019
Next Page
Close

Let's Open Free Demat Account